Aligos Therapeutics ALGS 深 沪
已收盘 10-24 16:00:00 美东时间
9.685
+0.195
+2.05%
华盛通- 最 高10.10
- 今 开9.60
- 成交量 5.30万股
- 最 低 9.47
- 昨 收 9.49
- 总市值 5922.18万
- 52周最高 46.80
- 市盈率 静 --
- 换手率 0.87%
- 52周最低 3.76
- 委 比 99.31%
- 总股本 611.48万
- 历史最高 937.75
- 量 比 0.71
- 振 幅 6.64%
- 历史最低 3.76
- 每 手 1
- 风险率 10.09%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多8 Analysts Assess Mirum Pharmaceuticals: What You Need To Know
Mirum Pharmaceuticals (NASDAQ:MIRM) has been analyzed by 8 analysts in the last...
10-17 04:00
Aligos Therapeutics Says USAN Council Adopts Pevifoscorvir Sodium As Generic Name For ALG-000184, Under Investigation For Treatment Of Chronic Hepatitis B Virus Infection
Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the United
10-16 20:35
Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184
Aligos Therapeutics announced that the USAN Council has adopted "pevifoscorvir sodium" as the generic name for its compound ALG-000184, under investigation for chronic hepatitis B treatment. The naming marks a milestone for Aligos, aligning with its commitment to innovative therapies. Pevifoscorvir sodium, derived from Emory University's IP and optimized by Aligos, is a potent oral capsid assembly modulator (CAM-E) showing promising results in Ph...
10-16 12:30
H.C. Wainwright Reaffirms Their Buy Rating on Aligos Therapeutics (ALGS)
In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a ...
10-15 21:55
Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025
Aligos Therapeutics will present eight abstracts, including one oral presentation, at The Liver Meeting 2025. Key highlights include data on ALG-000184, a novel capsid assembly modulator for chronic hepatitis B, demonstrating potent suppression of HBV DNA in treatment-naive or currently-not-treated subjects. Other presentations will focus on preclinical studies and emerging HBV therapeutics, including the effects of ALG-001075 on cccDNA formation...
10-07 12:30
美股大行评级 | 潜在涨幅280.95%！HC Wainwright & Co.上调Immix Biopharma目标价至8美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从7美元升至8美元；Maxim Group：上调CNS Pharma评级至"买入"，目标价20美元
09-15 11:13
HC Wainwright & Co. Reiterates Buy on Aligos Therapeutics, Maintains $50 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Aligos Therapeutics (NASDAQ:ALGS) with a Buy and maintains $50 price target.
09-12 23:27
Demystifying Mirum Pharmaceuticals: Insights From 6 Analyst Reviews
Providing a diverse range of perspectives from bullish to bearish, 6 analysts h...
09-12 21:01
Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting
Aligos Therapeutics announced six presentations, including three oral, at the 2025 International HBV Meeting in Berlin. The company highlighted advancements in therapies for liver and viral diseases, focusing on ALG-000184's effects on HBV cccDNA reduction and a novel ASO approach for HDV cure. CEO Lawrence Blatt emphasized innovation in HBV treatment and the expansion of their pipeline with the ASO program targeting HDV, which uniquely destroys ...
09-03 20:05
Aligos Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Aligos Therapeutics announced that its management will present at the H.C. Wainwright 27th Annual Global Investment Conference on Sept. 8-10, 2025. The presentation can be viewed on-demand via the company's website, with a replay available for 30 days. Aligos focuses on developing best-in-class therapies for liver and viral diseases, targeting unmet medical needs such as chronic hepatitis B, metabolic-associated steatohepatitis, and coronaviruses...
09-02 20:05
